BOOKMARK
  • Korean|
  • Chinese|
  • Japanese|
  • Vietnamese
본문내용 바로가기

Aju Business Daily

SEARCH
  • ECONOMY
  • ENTERTAINMENT
  • IT
  • South Korea
  • North Korea
  • WORLD
  • SPORTS
  • LIFESTYLE
  • AUTO MOTIVE
  • OPINION
  • PEOPLE
  • MILITARY
Home > Health > article

Clinical trials to test ten treatment and two vaccine candidates in S. Korea

Lim Chang-won Reporter(cwlim34@ajunews.com) | Posted : July 10, 2020, 15:52 | Updated : July 10, 2020, 15:52
  • 트위터
  • 페이스북
  • 웨이보

[Yonhap Photo]

SEOUL -- Clinical trials are underway in South Korea to test the safety and efficacy of ten treatment and two vaccine candidates. South Korea's health regulatory agency said that five more are under review to see if they are suitable for a national campaign to contain a new coronavirus pandemic. 

Candidates for remedies listed by the Ministry of Food and Drug Safety included camostat mesilate, ciclesonide, clevudine, nafamostat mesilate, ifenprodil, EC-18 (synthetic monoacetyldiglyceride), pyronaridine phosphate/Artesunate, and baricitinib sold under the brand name of Olumiant.

The two vaccines are GX-19, a DNA vaccine material developed by Genexine, a clinical-stage biotechnology company in South Korea, and INO-4800 developed by Inovio Pharmaceuticals, an American biotechnology company.

Genexine is involved in joint vaccine research in Indonesia, Thailand and Turkey. South Korea has unveiled a roadmap for the treatment of COVID-19 to develop plasma treatment by the year's end as well as antibody treatment and vaccines next year.

  • Lim Chang-won Reporter
  • email : cwlim34@ajunews.com
© Aju Business Daily & www.ajunews.com Copyright: All materials on this site may not be reproduced, distributed, transmitted, displayed, published or broadcast without the authorization from the Aju News Corporation.
  • twitter
  • facebook
  • weibo
  • link copy
  • LIST
  • TOP

Related news

  • .Experts give conditional consent to AstraZenecas vaccine for people over 65.
    Experts give conditional consent to AstraZeneca's vaccine fo…
  • .Bukwangs COVID-19 treatment wins FDA approve to go ahead with second-phase clinical trials.
    Bukwang's COVID-19 treatment wins FDA approve to go ahead wi…
  • .Russias Sputnik vaccine draws attention ahead of new CMO deal in S. Korea.
    Russia's Sputnik vaccine draws attention ahead of new CMO de…
  • .Kimchi refrigerator maker develops portable ultra-low temperature freezer for vaccines.
    Kimchi refrigerator maker develops portable ultra-low temper…
  • .Russian vaccine mentioned as potential option for vaccination in S. Korea  .
    Russian vaccine mentioned as potential option for vaccinatio…

Real Time Photo News

  • .Girl band (G)I-DLE shrinks size to five members after school bullying controversy.

    Girl band (G)I-DLE shrinks size to five members after school bullying controversy

  • .Singer-actress IU reveals release schedule for album LILAC.

    Singer-actress IU reveals release schedule for album 'LILAC'

  • .S. Korea to build state-run K-pop concert hall for unaffordable online performances .

    S. Korea to build state-run K-pop concert hall for unaffordable online performances

  • .BLACKPINK member Rosé to release solo album in March.

    BLACKPINK member Rosé to release solo album in March

  • .BTS agency posts record earnings in 2020 on brisk online activities and album sales .

    BTS agency posts record earnings in 2020 on brisk online activities and album sales

Latest News

more+

  • Girl band (G)I-DLE shrinks size to five members after school bullying controversy
  • S. Korean companies to build combined cycle power plant in Thailand
  • Transparent LED film displays videos and images at official venue of Busan film festival
  • Daredevil surfers to be fined for ignoring storm warning
  • Hanwha Techwin releases CCTVs with fog removal and other functions
Aju Business Daily
  • ABOUT US
  • CONTACT US
  • PRIVACY STATEMENT
  • Copyright Policy

Address : Aju News Corporation LEEMA Building, 11th floor, 42, Jong-ro 1-gil, Jongno-gu, Seoul.    Mail : swatchsjp@ajunews.com

Copyright ⓒ 2016 By Ajunews Corporation, All Rights Reserved.

Mobile view